Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2022

Open Access 02-06-2022 | Original Article

A comparison of advanced semi-quantitative amyloid PET analysis methods

Authors: Enrico Peira, Davide Poggiali, Matteo Pardini, Henryk Barthel, Osama Sabri, Silvia Morbelli, Annachiara Cagnin, Andrea Chincarini, Diego Cecchin

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2022

Login to get access

Abstract

Purpose

To date, there is no consensus on how to semi-quantitatively assess brain amyloid PET. Some approaches use late acquisition alone (e.g., ELBA, based on radiomic features), others integrate the early scan (e.g., TDr, which targets the area of maximum perfusion) and structural imaging (e.g., WMR, that compares kinetic behaviour of white and grey matter, or SI based on the kinetic characteristics of the grey matter alone). In this study SUVr, ELBA, TDr, WMR, and SI were compared. The latter — the most complete one — provided the reference measure for amyloid burden allowing to assess the efficacy and feasibility in clinical setting of the other approaches.

Methods

We used data from 85 patients (aged 44–87) who underwent dual time-point PET/MRI acquisitions. The correlations with SI were computed and the methods compared with the visual assessment. Assuming SUVr, ELBA, TDr, and WMR to be independent measures, we linearly combined them to obtain more robust indices. Finally, we investigated possible associations between each quantifier and age in amyloid-negative patients.

Results

Each quantifier exhibited excellent agreement with visual assessment and strong correlation with SI (average AUC = 0.99, ρ = 0.91). Exceptions to this were observed for subcortical regions with ELBA and WMR (ρELBA = 0.44, ρWMR = 0.70). The linear combinations showed better performances than the individual methods. Significant associations were observed between TDr, WMR, SI, and age in amyloid-negative patients (p < 0.05).

Conclusion

Among the other methods, TDr came closest to the reference with less implementation complexity. Moreover, this study suggests that combining independent approaches gives better results than the individual procedure, so efforts should focus on multi-classifier systems for amyloid PET. Finally, the ability of techniques integrating blood perfusion to depict age-related variations in amyloid load in amyloid-negative subjects demonstrates the goodness of the estimate.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Elliott C, Masliah E, Ryan L, Silverberg N. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018.CrossRef Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Elliott C, Masliah E, Ryan L, Silverberg N. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14(4):535–62. https://​doi.​org/​10.​1016/​j.​jalz.​2018.​02.​018.CrossRef
3.
go back to reference Fantoni ER, Chalkidou A, O’Brien JT, Farrar G, Hammers A. A Systematic review and aggregated analysis on the impact of amyloid PET Brain imaging on the diagnosis diagnostic confidence and management of patients being evaluated for Alzheimer’s disease. J Alzheimers Dis. 2018;63(2):4. https://doi.org/10.3233/JAD-171093.CrossRef Fantoni ER, Chalkidou A, O’Brien JT, Farrar G, Hammers A. A Systematic review and aggregated analysis on the impact of amyloid PET Brain imaging on the diagnosis diagnostic confidence and management of patients being evaluated for Alzheimer’s disease. J Alzheimers Dis. 2018;63(2):4. https://​doi.​org/​10.​3233/​JAD-171093.CrossRef
4.
go back to reference Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka S-K, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IHGB, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJB, van Waalwijk LJC, van Doorn G, Waldemar A, Wallin ÅK, Wallin J, Wiltfang DA, Wolk M. Zboch, Zetterberg H. Prevalence of cerebral amyloid pathology in persons without dementia. JAMA. 2015;313(19):5. https://doi.org/10.1001/jama.2015.4668.CrossRef Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka S-K, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IHGB, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJB, van Waalwijk LJC, van Doorn G, Waldemar A, Wallin ÅK, Wallin J, Wiltfang DA, Wolk M. Zboch, Zetterberg H. Prevalence of cerebral amyloid pathology in persons without dementia. JAMA. 2015;313(19):5. https://​doi.​org/​10.​1001/​jama.​2015.​4668.CrossRef
5.
10.
go back to reference A Chincarini, E Peira, S Morbelli, M Pardini, M Bauckneht, J Arbizu, M Castelo-Branco, K Büsing, A de Mendonça, M Didic, M Dottorini, S Engelborghs, C Ferrarese, G Frisoni, V Garibotto, E Guedj, L Hausner, J Hugon, J Verhaeghe, P Mecocci, M Musarra, M Queneau, M Riverol, I Santana, U Guerra and F Nobili. Semi-quantification and grading of amyloid PET: a project of the european Alzheimer’s Disease Consortium (EADC). NeuroImage Clin. 2019; 23:101846. https://doi.org/10.1016/j.nicl.2019.101846. A Chincarini, E Peira, S Morbelli, M Pardini, M Bauckneht, J Arbizu, M Castelo-Branco, K Büsing, A de Mendonça, M Didic, M Dottorini, S Engelborghs, C Ferrarese, G Frisoni, V Garibotto, E Guedj, L Hausner, J Hugon, J Verhaeghe, P Mecocci, M Musarra, M Queneau, M Riverol, I Santana, U Guerra and F Nobili. Semi-quantification and grading of amyloid PET: a project of the european Alzheimer’s Disease Consortium (EADC). NeuroImage Clin. 2019; 23:101846. https://​doi.​org/​10.​1016/​j.​nicl.​2019.​101846.
11.
go back to reference Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6. https://doi.org/10.1038/nature19323.CrossRefPubMed Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6. https://​doi.​org/​10.​1038/​nature19323.CrossRefPubMed
13.
go back to reference Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):1. https://doi.org/10.1056/NEJMoa1304839.CrossRef Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):1. https://​doi.​org/​10.​1056/​NEJMoa1304839.CrossRef
14.
go back to reference Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378(4):1. https://doi.org/10.1056/NEJMoa1705971.CrossRef Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378(4):1. https://​doi.​org/​10.​1056/​NEJMoa1705971.CrossRef
15.
go back to reference Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Brashear HR, Black RS. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):12. https://doi.org/10.1186/s13195-016-0189-7.CrossRef Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Brashear HR, Black RS. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):12. https://​doi.​org/​10.​1186/​s13195-016-0189-7.CrossRef
18.
go back to reference Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, Habert M-O, Dyrba M, Gonzalez-Escamilla G, Bertin H, Locatelli M, Lehericy S, Teipel S, Dubois B, Hampel H. Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimers Res Ther. 2019;11(1):12. https://doi.org/10.1186/s13195-019-0466-3.CrossRef Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, Habert M-O, Dyrba M, Gonzalez-Escamilla G, Bertin H, Locatelli M, Lehericy S, Teipel S, Dubois B, Hampel H. Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimers Res Ther. 2019;11(1):12. https://​doi.​org/​10.​1186/​s13195-019-0466-3.CrossRef
22.
go back to reference Chincarini A, Peira E, Corosu M, Morbelli S, Bauckneht M, Capitanio S, Pardini M, Arnaldi D, Vellani C, D’Ambrosio D, Garibotto V, Assal F, Paghera B, Savelli G, Stefanelli A, Guerra UP, Nobili F. A kinetics-based approach to amyloid PET semi-quantification. Eur J Nucl Med Mol Imaging. 2020;47(9):8. https://doi.org/10.1007/s00259-020-04689-y.CrossRef Chincarini A, Peira E, Corosu M, Morbelli S, Bauckneht M, Capitanio S, Pardini M, Arnaldi D, Vellani C, D’Ambrosio D, Garibotto V, Assal F, Paghera B, Savelli G, Stefanelli A, Guerra UP, Nobili F. A kinetics-based approach to amyloid PET semi-quantification. Eur J Nucl Med Mol Imaging. 2020;47(9):8. https://​doi.​org/​10.​1007/​s00259-020-04689-y.CrossRef
24.
go back to reference Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11(9):1050–68. https://doi.org/10.1016/j.jalz.2014.09.004.CrossRefPubMed Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11(9):1050–68. https://​doi.​org/​10.​1016/​j.​jalz.​2014.​09.​004.CrossRefPubMed
26.
go back to reference Garibotto V, Albert NL, Barthel H, van Berckel B, Boellaard R, Brendel M, Cecchin D, Ekmekcioglu O, van de Giessen E, Guedj E, Lammerstma AA, Semah F, Traub-Weidinger T, Van Weehaeghe D, Morbelli S. The approval of a disease-modifying treatment for Alzheimer’s disease: impact and consequences for the nuclear medicine community. Eur J Nucl Med Mol Imaging. 2021;48(10):3033–6. https://doi.org/10.1007/s00259-021-05485-y.CrossRefPubMed Garibotto V, Albert NL, Barthel H, van Berckel B, Boellaard R, Brendel M, Cecchin D, Ekmekcioglu O, van de Giessen E, Guedj E, Lammerstma AA, Semah F, Traub-Weidinger T, Van Weehaeghe D, Morbelli S. The approval of a disease-modifying treatment for Alzheimer’s disease: impact and consequences for the nuclear medicine community. Eur J Nucl Med Mol Imaging. 2021;48(10):3033–6. https://​doi.​org/​10.​1007/​s00259-021-05485-y.CrossRefPubMed
30.
go back to reference Müller EG, Stokke C, Stokmo HL, Edwin TH, Knapskog AB, Revheim ME. Evaluation of semi-quantitative measures of 18 F-flutemetamol PET for the clinical diagnosis of Alzheimer’s disease. Quant Imaging Med Surg. 2022;12(1):493–509.CrossRef Müller EG, Stokke C, Stokmo HL, Edwin TH, Knapskog AB, Revheim ME. Evaluation of semi-quantitative measures of 18 F-flutemetamol PET for the clinical diagnosis of Alzheimer’s disease. Quant Imaging Med Surg. 2022;12(1):493–509.CrossRef
33.
34.
go back to reference Schmitt J, Palleis C, Sauerbeck J, Unterrainer M, Harris S, Prix C, Weidinger E, Katzdobler S, Wagemann O, Danek A, Beyer L, Rauchmann BS, Rominger A, Simons M, Bartenstein P, Perneczky R, Haass C, Levin J, Höglinger GU, Brendel M, the German Imaging Initiative for Tauopathies (GII4T). Dual-phase β-amyloid PET Captures neuronal injury and amyloidosis in corticobasal syndrome. Front Aging Neurosci. 2021;13:661284. https://doi.org/10.3389/fnagi.2021.661284.CrossRefPubMedPubMedCentral Schmitt J, Palleis C, Sauerbeck J, Unterrainer M, Harris S, Prix C, Weidinger E, Katzdobler S, Wagemann O, Danek A, Beyer L, Rauchmann BS, Rominger A, Simons M, Bartenstein P, Perneczky R, Haass C, Levin J, Höglinger GU, Brendel M, the German Imaging Initiative for Tauopathies (GII4T). Dual-phase β-amyloid PET Captures neuronal injury and amyloidosis in corticobasal syndrome. Front Aging Neurosci. 2021;13:661284. https://​doi.​org/​10.​3389/​fnagi.​2021.​661284.CrossRefPubMedPubMedCentral
Metadata
Title
A comparison of advanced semi-quantitative amyloid PET analysis methods
Authors
Enrico Peira
Davide Poggiali
Matteo Pardini
Henryk Barthel
Osama Sabri
Silvia Morbelli
Annachiara Cagnin
Andrea Chincarini
Diego Cecchin
Publication date
02-06-2022
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-05846-1

Other articles of this Issue 12/2022

European Journal of Nuclear Medicine and Molecular Imaging 12/2022 Go to the issue